IL1B and myocardial infarction: Given these backgrounds, we conducted a meta‐analysis to summarize all published RCT studies to examine whether IL‐1 blockage treatment reduce the risk and incidence rate of overall major adverse cardiovascular events, all‐cause death, acute myocardial infarction, unstable angina and heart failure.